Clinical and biological features of t(4;14) multiple myeloma: A prospective study

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 238-246

  Karlin, Lionel ^a   Soulier, Jean ^a   Chandesris, Olivia ^b   Choquet, Sylvain ^c   Belhadj, Karim ^d   MacRo, Margaret ^e   Bouscary, Didier ^f   Porcher, Raphael ^a   Ghez, David ^b   Malphettes, Marion ^a   Asli, Bouchra ^a   Brouet, Jean Claude ^a   Bories, Jean Christophe ^a   Hermine, Olivier ^b   Fermand, Jean Paul ^a   Arnulf, Bertrand ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f Cochin Hospital ^*  (France)

Author keywords

bortezomib; heterogeneity; Multiple myeloma; prognosis; t(4; 14) translocation

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN A; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 4; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PYRAZINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SALVAGE THERAPY; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 79551630261     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.537795     Document Type: Article

References (34)

1. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 2005:346-352.
2. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185-2191.
3. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998;92:3025-3034.
4. Chandesris MO, Soulier J, Labaume S, et al. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma. Br J Haematol 2007;136:609-614.
5. Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003;102:2562-2567.
6. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003;101:1520-1529.
7. Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125:64-68.
8. Cavo M, Terragna C, Renzulli M, et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol 2006;24:e4-e5.
9. Moreau P, Attal M, Garban F, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007;21:2020-2024.
10. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalitiesin monoclonal gammopathy of undetermined significance. Blood 2002;100:1417-1424.
11. Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999;59: 4546-4550.
12. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
13. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412-5417.
14. Van Wier S, Ahmann G, Kimberly J, et al. The t(4;14) is present in patients with early stage plasma cell proliferative disorders including MGUS and smoldering multiple myeloma (SMM). Blood 2005;106(Suppl. 1): Abstract 1545.
15. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630-4634.
16. Tosi P, Terragna C, Testoni N, et al. Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. Eur J Haematol 2008; 80:31-36.
17. Attal M, Harousseau JL, Facon T, et al. Single versus ouble autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
18. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-3146.
19. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775-5782.
20. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008;140:625-634.
21. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518-521.
22. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
23. Rosinol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25:4452-4458.
24. Harousseau JL, Palumbo A, Richardson P, et al. Superior outcomes associated with complete response: analysis of the phase III VISTA study of bortezomib plus melphalan- prednisone versus melphalan-prednisone. Blood 2008;112 (Suppl. 1): Abstract 2778.
25. Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;23:7069-7073.
26. Niesvizky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 2008;143:46-53.
27. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110: 3557-3560.
28. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164-168.
29. Avet-Loiseau H, Soulier J, Fermand JP, et al. Impact of chromosomal abnormalities del(13), t(4;14), and del(17p) and prior treatment on outcomes in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2008;112(Suppl. 1): Abstract 3685.
30. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009;114:522-525.
31. Chng WJ, Jacobus S, Fonseca R. Do beta2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy? Leukemia 2008;22:1080-1081.
32. Xin X, Abrams TJ, Hollenbach PW, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2006;12:4908-4915.
33. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105:2941-2948.
34. Arnulf B, Ghez D, Leblond V, et al. FGFR3 tyrosine kinase inhibitor AB1010 as treatment of t(4;14) multiple myeloma. Blood 2007;110(Suppl. 1): Abstract 413.